Studies of the effect of thyroid dysfunction on the elimination of beta-adrenoreceptor blocking drugs.
作者信息
Bell J M, Russell C J, Nelson J K, Kelly J G, McDevitt D G
出版信息
Br J Clin Pharmacol. 1977 Feb;4(1):79-82. doi: 10.1111/j.1365-2125.1977.tb00672.x.
Abstract
摘要
相似文献
1
Studies of the effect of thyroid dysfunction on the elimination of beta-adrenoreceptor blocking drugs.甲状腺功能障碍对β-肾上腺素受体阻断药物消除作用的研究。
Br J Clin Pharmacol. 1977 Feb;4(1):79-82. doi: 10.1111/j.1365-2125.1977.tb00672.x.
2
Clinical pharmacokinetics of beta-adrenoceptor blocking drugs in thyroid disease.β-肾上腺素受体阻断药在甲状腺疾病中的临床药代动力学
Clin Pharmacokinet. 1983 Jan-Feb;8(1):1-16. doi: 10.2165/00003088-198308010-00001.
3
Effects of thyroid dysfunction on propranolol kinetics.甲状腺功能障碍对普萘洛尔动力学的影响。
Clin Pharmacol Ther. 1980 Nov;28(5):565-74. doi: 10.1038/clpt.1980.204.
4
Pindolol: a pharmacokinetic comparison with other beta-adrenoceptor blocking agents.吲哚洛尔：与其他β-肾上腺素能受体阻滞剂的药代动力学比较。
Acta Med Scand Suppl. 1977;606:65-70. doi: 10.1111/j.0954-6820.1977.tb18031.x.
5
Drug pharmacokinetics in thyroid dysfunction.
Minerva Endocrinol. 1985 Apr-Jun;10(2):97-113.
6
[Comparative pharmacokinetics of beta-blockers].[β受体阻滞剂的比较药代动力学]
Nouv Presse Med. 1978 Sep 20;7(31):2685-7.
7
No enhanced elimination of propranolol in patients with hyperthyroidism.甲状腺功能亢进患者中普萘洛尔无增强消除作用。
Res Commun Chem Pathol Pharmacol. 1980 Sep;29(3):473-85.
8
[Biotransformation and pharmacokinetics of beta-receptor blockaders].β受体阻滞剂的生物转化与药代动力学
Pharmazie. 1975 Oct;30(10):625-33.
9
The uptake and overflow of radiolabelled beta-adrenoceptor blocking agents by the isolated vas deferens of the rat.放射性标记的β-肾上腺素能受体阻断剂在大鼠离体输精管中的摄取与溢出
Br J Pharmacol. 1977 Aug;60(4):595-600. doi: 10.1111/j.1476-5381.1977.tb07540.x.
10
Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs.β-肾上腺素受体阻断药的临床药代动力学
Clin Pharmacokinet. 1976;1(4):233-63. doi: 10.2165/00003088-197601040-00001.
引用本文的文献
1
No Dataset Left Behind: Mechanistic Insights into Thyroid Receptor Signaling Through Transcriptomic Consensome Meta-Analysis.无数据集被遗漏：通过转录组共识组元分析深入了解甲状腺受体信号转导的机制。
Thyroid. 2020 Apr;30(4):621-639. doi: 10.1089/thy.2019.0307. Epub 2020 Jan 29.
2
Absence of changes in drug disposition and catecholamine sensitivity in the hyperthyroid dog.甲状腺功能亢进犬的药物处置和儿茶酚胺敏感性无变化。
Br J Pharmacol. 1980;71(1):143-55. doi: 10.1111/j.1476-5381.1980.tb10919.x.
3
Plasma propranolol steady state concentrations in thyroid disorders.
Eur J Clin Pharmacol. 1981;19(5):329-33. doi: 10.1007/BF00544582.
4
Left ventricular function in hypothyroidism. Responses to exercise and beta adrenoceptor blockade.甲状腺功能减退症患者的左心室功能。对运动和β肾上腺素能受体阻滞剂的反应。
Br Heart J. 1982 Sep;48(3):278-84. doi: 10.1136/hrt.48.3.278.
5
Pharmacokinetics of propranolol and sotalol in hyperthyroidism.普萘洛尔和索他洛尔在甲状腺功能亢进症中的药代动力学。
Eur J Clin Pharmacol. 1982;21(5):373-7. doi: 10.1007/BF00542321.
6
A standard approach to compiling clinical pharmacokinetic data.一种汇编临床药代动力学数据的标准方法。
J Pharmacokinet Biopharm. 1981 Feb;9(1):59-127. doi: 10.1007/BF01059343.
7
Pharmacokinetics and pharmacodynamics of propranolol stereoisomers in hyperthyroid patients.普萘洛尔立体异构体在甲状腺功能亢进患者中的药代动力学和药效学。
Eur J Clin Pharmacol. 1981 Feb;19(3):197-203. doi: 10.1007/BF00561949.
8
Influence of thyroid dysfunction on drug pharmacokinetics.甲状腺功能障碍对药物药代动力学的影响。
Clin Pharmacokinet. 1981 Jul-Aug;6(4):275-97. doi: 10.2165/00003088-198106040-00003.
9
Use of beta-adrenoceptor blocking drugs in hyperthyroidism.β-肾上腺素能受体阻断药在甲状腺功能亢进症中的应用。
Drugs. 1984 May;27(5):425-46. doi: 10.2165/00003495-198427050-00003.
10
Clinical pharmacokinetics of beta-adrenoceptor blocking drugs in thyroid disease.β-肾上腺素受体阻断药在甲状腺疾病中的临床药代动力学
Clin Pharmacokinet. 1983 Jan-Feb;8(1):1-16. doi: 10.2165/00003088-198308010-00001.
本文引用的文献
1
Plasma propranolol levels in adults with observations in four children.成人血浆普萘洛尔水平及对四名儿童的观察结果
Clin Pharmacol Ther. 1970 Jan-Feb;11(1):112-20. doi: 10.1002/cpt1970111112.
2
Blood levels of practolol after oral and parenteral administration and their relationship to exercise heart rate.口服和肠胃外给药后心得宁的血药浓度及其与运动心率的关系。
Clin Pharmacol Ther. 1974 May;15(5):497-509. doi: 10.1002/cpt1974155497.
3
Influence of thyroid status on plasma half-life of antipyrine in man.
N Engl J Med. 1974 May 9;290(19):1040-2. doi: 10.1056/NEJM197405092901902.
4
The pharmacokinetics of propylthiouracil.丙硫氧嘧啶的药代动力学。
Acta Pharmacol Toxicol (Copenh). 1974 Nov;35(5):361-9. doi: 10.1111/j.1600-0773.1974.tb00756.x.
5
Pharmacokinetic studies of practolol, a beta adrenergic antagonist, in man.β肾上腺素能拮抗剂心得宁在人体的药代动力学研究。
Clin Pharmacol Ther. 1973 Jan-Feb;14(1):26-9. doi: 10.1002/cpt197314126.
6
Pharmacokinetic properties of the beta-adrenergic receptor blocking drugs.β-肾上腺素能受体阻断药物的药代动力学特性。
Drugs. 1974;7(1):39-47. doi: 10.2165/00003495-197407010-00003.
7
Beta-adrenergic receptor blocking drugs in hyperthyroidism.β肾上腺素能受体阻滞剂在甲状腺功能亢进症中的应用
Drugs. 1974;7(1):48-54. doi: 10.2165/00003495-197407010-00004.
8
Inhibition of drug metabolism in man.人体中药物代谢的抑制作用。
Drug Metab Dispos. 1973 Jan-Feb;1(1):402-10.
9
5-Hydroxytryptamine (5-HT) in the whole-blood of patients with depressive illness.抑郁症患者全血中的5-羟色胺（5-HT）
Postgrad Med J. 1976 Mar;52(605):156-8. doi: 10.1136/pgmj.52.605.156.
10
The kinetics of propylthiouracil in hyperthyroidism.丙硫氧嘧啶在甲状腺功能亢进症中的动力学
Acta Pharmacol Toxicol (Copenh). 1975 Sep;37(3):201-10. doi: 10.1111/j.1600-0773.1975.tb00836.x.
Zotero 插件